Janus Investment Fund · net assets $5.81B · 108 holdings as of June 30, 2026. Monthly N-PORT disclosure: the full book, not just equities.
EC: 99.1% · STIV: 0.9% · EP: 0.0% · OTHER: 0.0% · DO: 0.0%
| Month 1 | Month 2 | Month 3 | |
|---|---|---|---|
| Sales | $71.3M | $63.8M | $58.5M |
| Reinvestment | $-5.34 | $0 | $0 |
| Redemptions | $83.5M | $75.7M | $85.1M |
| Net realized gain (non-derivative) | $20.1M | $1.56M | $73.7M |
| Net unrealized appreciation (non-derivative) | $74.5M | $122M | $364M |
The three months of the reporting period, as filed; month 3 ends June 30, 2026.
| Holding | Value | % of net assets |
|---|---|---|
| Eli Lilly & Co. EC | $546M | 9.41% |
| Johnson & Johnson EC | $412M | 7.09% |
| Abbvie, Inc. EC | $271M | 4.67% |
| Unitedhealth Group, Inc. EC | $264M | 4.54% |
| Astrazeneca PLC EC | $228M | 3.93% |
| Revolution Medicines, Inc. EC | $175M | 3.02% |
| Argenx Se EC | $153M | 2.63% |
| Novartis Ag EC | $149M | 2.56% |
| Thermo Fisher Scientific, Inc. EC | $135M | 2.33% |
| Praxis Precision Medicines, Inc. EC | $127M | 2.19% |
| Bridgebio Pharma, Inc. EC | $118M | 2.04% |
| Cvs Health Corp. EC | $117M | 2.02% |
| Roche Holding Ag EC | $117M | 2.01% |
| Intuitive Surgical, Inc. EC | $113M | 1.94% |
| Merck & Co., Inc. EC | $109M | 1.87% |
| Abbott Laboratories EC | $108M | 1.86% |
| Vertex Pharmaceuticals, Inc. EC | $98.3M | 1.69% |
| Ascendis Pharma A/s EC | $97.5M | 1.68% |
| Danaher Corp. EC | $95.7M | 1.65% |
| Amgen, Inc. EC | $95.1M | 1.64% |
| Sanofi Sa EC | $91.8M | 1.58% |
| Stryker Corp. EC | $82M | 1.41% |
| Ptc Therapeutics, Inc. EC | $81.2M | 1.40% |
| Gilead Sciences, Inc. EC | $80.5M | 1.39% |
| Travere Therapeutics, Inc. EC | $80.3M | 1.38% |
| Madrigal Pharmaceuticals, Inc. EC | $78.1M | 1.34% |
| Hca Healthcare, Inc. EC | $73.5M | 1.26% |
| Mirum Pharmaceuticals, Inc. EC | $65.4M | 1.13% |
| Boston Scientific Corp. EC | $65.3M | 1.12% |
| Teva Pharmaceutical Industries Ltd. EC | $63.8M | 1.10% |
| United Therapeutics Corp. EC | $62.2M | 1.07% |
| Elevance Health, Inc. EC | $60.6M | 1.04% |
| Globus Medical, Inc. EC | $58.8M | 1.01% |
| Lantheus Holdings, Inc. EC | $56.4M | 0.97% |
| Mckesson Corp. EC | $55.8M | 0.96% |
| Vaxcyte, Inc. EC | $54.8M | 0.94% |
| Dyne Therapeutics, Inc. EC | $50.5M | 0.87% |
| Edwards Lifesciences Corp. EC | $45.3M | 0.78% |
| Medtronic PLC EC | $43M | 0.74% |
| Janus Henderson Cash Liquidity Fund LLC STIV | $40.5M | 0.70% |
| Cencora, Inc. EC | $34.9M | 0.60% |
| Ucb Sa EC | $33.8M | 0.58% |
| Medline, Inc. EC | $33.6M | 0.58% |
| Definium Therapeutics, Inc. EC | $33.4M | 0.58% |
| Insmed, Inc. EC | $32.6M | 0.56% |
| Dexcom, Inc. EC | $31.1M | 0.54% |
| Structure Therapeutics, Inc. EC | $29.5M | 0.51% |
| Spyre Therapeutics, Inc. EC | $29.2M | 0.50% |
| Ideaya Biosciences, Inc. EC | $28.2M | 0.49% |
| Glaukos Corp. EC | $27.5M | 0.47% |
| Apogee Therapeutics, Inc. EC | $27.5M | 0.47% |
| Edgewise Therapeutics, Inc. EC | $27.5M | 0.47% |
| Becton Dickinson & Co. EC | $26.6M | 0.46% |
| Abivax Sa EC | $23.9M | 0.41% |
| Neurocrine Biosciences, Inc. EC | $22.7M | 0.39% |
| Tarsus Pharmaceuticals, Inc. EC | $21.8M | 0.38% |
| Centene Corp. EC | $21.2M | 0.37% |
| Oruka Therapeutics, Inc. EC | $21.1M | 0.36% |
| Xenon Pharmaceuticals, Inc. EC | $20.2M | 0.35% |
| Cogent Biosciences, Inc. EC | $20.1M | 0.35% |
Showing top 60 of 108 holdings.
Loading...
